Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of glucocorticoids on anti-infective efficacy and prognosis of children with bronchiolitis caused by <i>Mycoplasma pneumoniae</i>
Abstract
Purpose: To investigate the effect of glucocorticoid administration on anti-infective efficacy and prognosis of children diagnosed with bronchiolitis caused by Mycoplasma pneumoniae (MP).
Methods: 100 children from January 2021 to June 2023 diagnosed with MP- induced bronchiolitis at the Department of Pediatrics, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China were randomized into study (n = 45) and control groups (n = 55). The study group received conventional medication (azithromycin at 10 mg/kg on the first day followed by 5 mg/kg/day for 5 days) in addition to glucocorticoids, while control group received the same conventional medication without glucocorticoids. The study group was treated with prednisone (2 mg/kg/day), once a day for 5 days. Inflammatory markers (C-reactive protein (CRP) and procalcitonin (PCT) levels) before and after treatment, duration of medication, disease course, clinical efficacy, and prognosis were compared.
Results: There was no significant difference in baseline characteristics between both groups (p > 0.05). The study group showed significantly reduced CRP and PCT levels, shorter medication and disease duration, and a higher efficacy compared to control group (p < 0.05).
Conclusions: Administration of glucocorticoids in addition to conventional medication in MP-induced bronchiolitis reduces levels of inflammatory markers, improves clinical symptoms, and enhances efficacy. Future studies using prospective, randomized controlled trials, larger sample sizes that cut across multicenter sites, standardized treatment protocols, and long-term follow-up will be required to more accurately confirm the safety and efficacy of glucocorticoids in the management of MP-induced bronchiolitis.
